We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current AMRX market cap is 2.57B. The company's latest EPS is USD -0.2713 and P/E is -21.64.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 602.5M | 617.89M | 629.65M | 659.19M | 701.78M |
| Operating Income | 80.08M | 75.65M | 14.19M | -10.65M | 95.47M |
| Net Income | 11.92M | 9.68M | -98.65M | -91.64M | 5.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.63B | 1.99B | 2.09B | 2.22B | 2.41B |
| Operating Income | -248.68M | 91.16M | 158.08M | -96.84M | 204.37M |
| Net Income | -361.92M | 91.06M | 10.62M | -129.99M | -83.99M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.7B | 3.69B | 3.47B | 3.46B | 3.51B |
| Total Liabilities | 3.52B | 3.5B | 3.41B | 3.47B | 3.51B |
| Total Equity | 150.77M | 154.24M | 20.01M | -63.63M | -57.49M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.67B | 4.01B | 3.94B | 3.8B | 3.47B |
| Total Liabilities | 3.32B | 3.65B | 3.56B | 3.59B | 3.41B |
| Total Equity | 346.79M | 344.93M | 366.97M | 183.98M | 20.01M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 128.37M | 209.75M | 345.58M | -4.41M | 35.25M |
| Investing | -24.02M | -37.5M | -69.19M | -19.76M | -26.23M |
| Financing | -25.16M | -111.74M | -212.57M | -23.16M | -58.24M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 1.71M | 379M | 241.82M | 65.1M | 345.58M |
| Investing | -19.58M | -317.55M | -194.18M | -174.31M | -69.19M |
| Financing | -45.83M | 131.81M | -138.12M | -106.62M | -212.57M |
| Market Cap | 2.57B |
| Price to Earnings Ratio | -21.64 |
| Price to Sales Ratio | 0.75 |
| Price to Cash Ratio | 19.85 |
| Price to Book Ratio | 29.64 |
| Dividend Yield | - |
| Shares Outstanding | 309.54M |
| Average Volume (1 week) | 1.57M |
| Average Volume (1 Month) | 1.1M |
| 52 Week Change | 41.18% |
| 52 Week High | 9.475 |
| 52 Week Low | 5.01 |
| Spread (Intraday) | 10.65 (56.41%) |
| Company Name | Amneal Pharmaceuticals Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.amneal.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
